The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
ApexOnco Front Page
Recent articles
Biopharma's interest in CDH17 and CDH6 continues, courtesy of Lepu and Qilu.
The company stops dosing in the troubled Tamarack trial, and is going quiet until ESMO.
But the company hasn’t given details, and used a historical control rather than the study’s own control arm.
Meanwhile, the RayzeBio-originated RYZ101 is back in Action.
Now in Bristol’s hands, BMS-986442 is set to deliver its first clinical data.
But Imfinzi's precise setting is uncertain, and big problems loom for companies pursuing similar trials.
Roche curbs its TIGIT push, while a co-stimulation crunch could be bad news for Regeneron.